A Redox-Dependent Mechanism for Regulation of AMPK Activation by Thioredoxin1 during Energy Starvation  by Shao, Dan et al.
Cell Metabolism
ArticleA Redox-Dependent Mechanism
for Regulation of AMPK Activation
by Thioredoxin1 during Energy Starvation
Dan Shao,1 Shin-ichi Oka,1 Tong Liu,2 Peiyong Zhai,1 Tetsuro Ago,1 Sebastiano Sciarretta,1 Hong Li,2
and Junichi Sadoshima1,*
1Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, New Jersey Medical School
2Center for Advanced Proteomics Research and Department of Biochemistry and Molecular Biology, New Jersey Medical School
Cancer Center
Rutgers Biomedical and Health Sciences, Newark, NJ 07103, USA
*Correspondence: sadoshju@njms.rutgers.edu
http://dx.doi.org/10.1016/j.cmet.2013.12.013SUMMARY
50-AMP-activated protein kinase (AMPK) is a key
regulator of metabolism and survival during energy
stress. Dysregulation of AMPK is strongly associated
with oxidative-stress-related disease. However,
whether and how AMPK is regulated by intracellular
redox status remains unknown. Here we show that
the activity of AMPK is negatively regulated by oxida-
tion of Cys130 and Cys174 in its a subunit, which
interferes with the interaction between AMPK and
AMPK kinases (AMPKK). Reduction of Cys130/
Cys174 is essential for activation of AMPK during
energy starvation. Thioredoxin1 (Trx1), an important
reducing enzyme that cleaves disulfides in proteins,
prevents AMPK oxidation, serving as an essential
cofactor for AMPK activation. High-fat diet con-
sumption downregulates Trx1 and induces AMPK
oxidation, which enhances cardiomyocyte death
during myocardial ischemia. Thus, Trx1 modulates
activation of the cardioprotective AMPK pathway
during ischemia, functionally linking oxidative stress
and metabolism in the heart.
INTRODUCTION
Reactive oxygen species (ROS) are continuously generated by
cells to regulate cellular responses such as proliferation, differ-
entiation, and apoptosis (Finkel, 2003). ROS modulate signaling
molecules through reversible posttranslational reductive and
oxidative modification of protein structures. Specific cysteine
thiol groups (R-SH) are oxidized to sulfenic acid (R-SOH),
followed by rapid interaction with other protein thiol groups to
form disulfide bonds. Disulfide bond formation within redox-
sensitive proteins regulates subcellular localization, protein-
protein interactions, and protein structure, thereby regulating
their functional activity. Sulfenic acid is vulnerable to further,
largely irreversible, oxidation, forming either sulfinic acid
(R-SO2
2) or sulfonic acid (R-SO3
2) (Berndt et al., 2007). Excess232 Cell Metabolism 19, 232–245, February 4, 2014 ª2014 Elsevier InROS generation, termed oxidative stress, is involved in the path-
ogenesis of various diseases, such as cardiovascular disease,
neurodegenerative disease, and inflammation. However, under
physiological conditions, excess ROS are usually removed by
scavenging systems such as thioredoxin (Trx) and glutathione
(GSH) (Berndt et al., 2007).
Mammalian Trx1 contains a common disulfide active motif,
Cys-Gly-Pro-Cys. Trx1 catalyzes disulfide reduction through a
thiol-disulfide exchange reaction involving Cys32 and Cys35 in
its active site, leaving the target protein reduced and Trx1
oxidized (Kallis and Holmgren, 1980). Oxidized Trx1 is reduced
and regenerated by Trx1 reductase using electrons fromNADPH
(Mustacich and Powis, 2000). Trx1 acts both as a major disulfide
reductase, thereby maintaining the cellular thiol redox homeo-
stasis, and as a modulator of transcription factors and kinases,
regulating their activities in a redox-dependent manner (Lillig
and Holmgren, 2007).
ROS, produced bymitochondrial leakage and other enzymatic
sources, are associated with cardiovascular diseases. Trx1
activity is essential for reducing oxidative stress, inhibiting
cardiac hypertrophy, and attenuating cardiac cell death (Ago
et al., 2008). Trx1 not only maintains the intracellular redox
balance by regenerating active peroxiredoxin but also acts as
a signaling molecule to transduce signals to other effectors.
For example, Trx1 inhibits apoptosis by negatively regulating
apoptosis signal-regulating kinase (ASK1) and Ras in cardio-
myocytes (Kuster et al., 2005; Saitoh et al., 1998) and prevents
cardiac hypertrophy by reducing Class II histone deacetylases
(HDACs) and inhibiting their nuclear export (Ago et al., 2008).
Identification of the molecular targets of Trx1 is therefore an
important step in understanding the key signaling events
mediating cardiovascular pathogenesis.
Using unbiased proteomic approaches, we showed that Trx1
reduces proteins involved in cardiac energy dynamics (Fu et al.,
2009). Trx1 also plays an important protective role during
ischemia and reperfusion, which cause energy stress and even-
tual cell death in the heart (Tao et al., 2004). We predict that Trx1
protects the heart by reducing critical molecules involved in
energy and metabolism. Currently, however, functionally rele-
vant targets of Trx1 during myocardial ischemia are unknown.
During myocardial ischemia, the low-energy sensor, 50-AMP-
activated protein kinase (AMPK), is activated and stimulatesc.
Figure 1. Identifying AMPKa as a Trx1 Substrate during Myocardial Ischemia
(A) The principle of trapping Trx1 substrates. Left panel shows normal reduction of a disulfide bond by Trx1. Right panel shows trapping of a protein with a
disulfide bond by the Trx1-trapping mutant (Trx1C35S), in which the second cysteine in the CXXC active site has been replaced by serine. Trx1C35S forms a
mixed disulfide bond with the target protein. The resulting complex can be purified and the trapped protein identified by immunoblot analysis.
(B) Tg-Trx1, Tg-Trx1C35S, Tg-Trx1C32S/C35S, and control WTmice were subjected to ischemia for 3 hr. The myocardial infarct area/area at risk (% infarct size/
AAR) is shown (*p < 0.05 versus WT; #p < 0.05 versus Tg-Trx1; n = 4–6).
(C) Tg-Trx1C35S and WT mice were subjected to ischemia for 20 min. Homogenates prepared from sham-operated hearts and ischemic areas were used for
coimmunoprecipitation, and immunoblots for the indicated molecules were performed. Error bars represent SEM.
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(Russell et al., 2004). AMPK activity is tightly regulated at
Thr172 in its activation segment by phosphorylation by AMPK
kinases (AMPKKs) or allosteric prevention of dephosphorylation
when high levels of AMP or ADP bind to the g subunit (Hawley
et al., 1996; Oakhill et al., 2011). Due to its master role in control-
ling both cellular and whole-body metabolic responses, AMPK is
becoming a promising therapeutic target for insulin resistance,
type 2 diabetes, metabolic syndrome, and obesity, all energy
balance disorders (Hardie, 2008). Complications of these meta-
bolic disorders, which occur more frequently with aging, are
associated with chronic ROS accumulation and correlate with
insensitivity of AMPK activation to various stimuli (Reznick
et al., 2007; Sciarretta et al., 2012; Sriwijitkamol et al., 2007).
However, whether direct posttranslational oxidativemodification
affects AMPK activity during metabolic stress is currently
unknown.
Using mice harboring a Trx1 substrate-trapping mutant, we
identified AMPKa as a target of Trx1 that is critical to cardiac
protection against ischemia. During myocardial ischemia, oxida-
tion of Cys130 andCys174 causes aggregation of AMPK through
intermolecular disulfide bond formation, which prevents phos-Cell Mphorylation/activation of AMPKby upstreamAMPKKs. However,
endogenous Trx1 prevents this oxidation in response to
oxidative stimulus. High-fat diet (HFD) consumption decreased
Trx1 expression and increased AMPK oxidation, enhancing
susceptibility to myocardial infarction. Thus, AMPK activation is
critically regulated by intracellular redox status, and Trx1 acts
as an essential cofactor, allowing AMPK activation to occur
during energy stress by preventing oxidative aggregation.
RESULTS
AMPK Is a Direct Target of Trx1
Mutation of Cys35 in the catalytic center to serine (C35S) allows
Trx1 to trap its substrates by preventing completion of the thiol-
disulfide exchange reaction (Figure 1A) (Verdoucq et al., 1999). In
order to identify cardiac Trx1 targets in vivo, we generated
transgenic mice with cardiac-specific expression of epitope
(N-terminal FLAG and C-terminal HA)-tagged Trx1C35S (Tg-
Trx1C35S). Three lines of transgenic mice were generated, and
the one with the lowest transgene expression (line 1, Figure S1A,
available online) was used in further experiments. All three lines
exhibited apparently normal baseline cardiac phenotypes,etabolism 19, 232–245, February 4, 2014 ª2014 Elsevier Inc. 233
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trophy (Figure S1B). To examine the role of Trx1 during energy
starvation in vivo, mice were subjected to myocardial ischemia,
and the extent of myocardial infarction was evaluated. Trans-
genic mice with cardiac-specific overexpression of Trx1 (Tg-
Trx1) exhibited significantly less myocardial infarction, whereas
Tg-Trx1C35S mice and transgenic mice with cardiac-specific
overexpression of a dominant negative Trx1 mutant (C32S/
C35S) (Tg-Trx1C32S/C35S) had significantly more infarction
than wild-type (WT) mice after 3 hr of ischemia (Figure 1B). The
percentage of Hairpin-2 positive nuclei, indicating necrotic cell
death, was significantly lower in Tg-Trx1, but higher in Tg-
Trx1C35S and Tg-Trx1C32S/C35S, than in WT mice after
ischemia (Figure S1C). These data suggest that the Trx1 thiol-
disulfide exchange reaction protects the heart against prolonged
ischemia.
To identify the Trx1 substrates involved in this cardioprotec-
tion, heart homogenates were prepared from WT and Tg-
Trx1C35S mice, and proteins that form a disulfide bond with
Cys32 of Trx1C35S were coprecipitated with a FLAG antibody
and analyzed by immunoblot. N-Ethylmaleimide (NEM)
(20 mM) was added to the lysis buffer to block free thiol groups
and prevent spontaneous cysteine oxidation during protein
sample extraction, which can lead to nonspecific capture by
the Trx1-trapping mutant. Peroxiredoxin, a well-known Trx1
target, was one of the proteins identified through this analysis
(Figure S1D), confirming the efficacy of the trapping mutant
in vivo. Of the proteins identified (Figures 1C and S1D; Table
S1), we focused on the AMPK a subunit because of its impor-
tance in protecting the heart against ischemic injury (Russell
et al., 2004) and the absence of prior evidence that thiol-disulfide
exchange is involved in its regulation.
Endogenous AMPKa and Trx1 were present in both cytosol
and nucleus in cardiomyocytes (Figures 2A and 2B), and they
interacted with one another in both cardiomyocytes in vitro
and the heart in vivo (Figure 2C). To determine whether AMPKa
forms a disulfide bond with Trx1, their interaction was examined
after mutation of the Trx1 active site. H2O2 enhanced interaction
of AMPKa with Trx1C35S, but not with WT Trx1 or Trx1C32S/
C35S (Figure 2D). The interaction between Trx1C35S and
AMPKa was almost completely abolished by addition of dithio-
threitol (DTT), a reducing agent that cleaves disulfide bonds (Fig-
ure 2E). These results suggest that AMPKa and Trx1 interact at
baseline and that oxidative stress further stimulates disulfide
bond formation between AMPKa and Cys32 in Trx1C35S. The
expected increase in intermolecular disulfide bond formation
between AMPKa and WT Trx1 in response to H2O2 was not
apparent due to completion of the thiol-disulfide exchange reac-
tion via the reduced Cys35 in WT Trx1. Overexpression of WT
Trx1, but not C35S or C32S/C35S mutants, prevented AMPK
inactivation in response to H2O2 (Figure S2A), indicating that
the enzymatic activity of Trx1 is required to maintain AMPK
activity in the presence of oxidative stress.
Phosphorylation of AMPKa and its substrate acetyl-CoA
carboxylase (ACC) was increased in the ischemic heart. How-
ever, the increase in phosphorylation was abolished in Tg-
Trx1C35S and Tg-Trx1C32S/C35S mice (Figures 2F and S2B),
suggesting that the oxidoreductase activity of Trx1 is required
for ischemia-induced AMPK activation in vivo.234 Cell Metabolism 19, 232–245, February 4, 2014 ª2014 Elsevier InTrx1 Acts as a Cofactor of AMPK in Response to Energy
Stress
An adenovirus harboring Trx1 shRNA (Ad-sh-Trx1) significantly
inhibited glucose-deprivation (GD)-induced phosphorylation of
both AMPKa and ACC in cardiomyocytes (Figure 3A), indicating
that endogenous Trx1 plays an essential role in mediating AMPK
activation in vitro.
AMPK activation during energy stress induces translocation of
glucose transporter 4 (Glut4), which in turn stimulates glycolysis
in cardiomyocytes (Russell et al., 2004). Immunostaining and
immunoblot analyses of the membrane fraction showed that
Trx1 downregulation disrupted GD-induced Glut4 transloca-
tion to the plasma membrane (Figures 3B and S3A). GD-
induced phosphorylation of phosphofructokinase 2 (PFK-2)
and increases in the glycolysis rate were also attenuated in
Ad-sh-Trx1-treated cardiomyocytes (Figure 3C). GD-induced
decreases in ATP content and cell survival were exacerbated
in cardiomyocytes treated with Ad-sh-Trx1 compared to in those
with Ad-sh-scramble (Figures 3D and S3B). This effect was
similar to that observed with dominant negative AMPK
adenovirus (Ad-dn-AMPK) (Figures 3D and S3B). Suppression
of AMPK in the presence of Trx1 downregulation did not further
increase GD-induced cell death (Figure 3D). On the other hand,
overexpression of either AMPK or Trx1 prevented GD-induced
cell death (Figures S3C and S3D). Together, these data suggest
that Trx1 plays an essential role in mediating AMPK activation
and adaptive responses during GD.
Interestingly, both GD and 5-amino-1-b-Dffff-ribofuranosyl-
imidazole-4-carboxamide (AICAR), which activates AMPK, also
upregulated Trx1, an effect that was abolished in the presence
of Ad-dn-AMPK (Figures S3E and S3F). Thus, AMPK activation
is necessary and sufficient for Trx1 upregulation, suggesting
that AMPK and Trx1 coordinately regulate each other during
energy stress.
Trx1 Prevents Oxidation of AMPK in Response to Energy
Stress
Since the oxidoreductive activity of Trx1 is required for AMPK
activation during energy stress, we hypothesized that AMPKa
undergoes oxidative modification. GD significantly induced
H2O2 production, as evaluated with CM-H2DCFDA staining (Fig-
ure S4A). In order to examine whether AMPKa exhibits an elec-
trophoretic mobility shift indicative of oxidative modification in
response to energy stress, cardiomyocytes were incubated
with glucose-free medium. Cardiomyocytes were also treated
with H2O2 as an exogenous oxidant to examine oxidation of
AMPK. Cell lysates were separated by SDS-PAGE under nonre-
ducing conditions in the absence of b-mercaptoethanol (BME).
Duplicate samples were run on 6%and 8%gels in order to sepa-
rate both high- and low-molecular-weight proteins reactive with
the AMPKa antibody (Figure S4B). Immunoblot analyses
revealed that AMPKa shifted to high molecular weights, and
monomeric AMPKa was decreased in GD- or H2O2-treated
myocytes (Figures 4A and 4B). BME abolished these mobility
shifts, suggesting that the slow-migrating AMPKa immunoreac-
tive complex most likely represents oxidative aggregation
caused by disulfide bond formation (Figures 4A and 4B). Trx1
downregulation significantly weakened the monomer and
increased the shift of AMPKa to higher molecular weights duringc.
Figure 2. AMPK Interacts with the Active Site of Trx1
(A) Myocytes were stained with AMPKa antibody (red), Trx1 antibody (green), and DAPI (blue).
(B) The presence of AMPKa and Trx1 was examined in cytosolic and nuclear fractions prepared from neonatal cardiomyocytes.
(C) Interaction between AMPKa and Trx1 was examined. Results are representative of three individual experiments.
(D and E) Cos7 cells were transfected with N-terminal FLAG- and C-terminal HA-tagged Trx1 WT (FLAG-Trx1-HA) or mutant plasmids.
(D) Cells transfected with the indicated plasmids were treated with or without 100 mM H2O2 for 30 min. Interaction between AMPKa and Trx1 mutants was
examined. Statistical analysis of the immunoblot densitometric measurements is shown (*p < 0.05 versus WT/H2O2; #p < 0.05 versus C35S/H2O2; n = 3).
(E) Cells transfected with the indicated plasmids were treated with or without 100 mM H2O2 for 30 min and lysed with or without 1 mM DTT. Immunoblots with
AMPKa and HA antibodies are shown.
(F) Tg-Trx1C35S andWTmice were subjected to ischemia for 20 min. Homogenates prepared from sham-operated hearts and the ischemic areas were used for
immunoblot analyses of p-AMPKa, AMPKa, p-ACC, ACC, and Trx1. Statistical analyses of densitometric measurements of p-AMPKa and p-ACC are shown
(*p < 0.05 versus WT/sham; #p < 0.05 versus WT/ischemia; n = 3–5). Error bars represent SEM.
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endogenous Trx1 is essential in preventing AMPKa oxidation.
Increased oxidative aggregation and decreased monomeric
AMPKa were also observed in ischemic hearts (Figure S4C),
suggesting AMPKa disulfide bond formation in vivo. Electropho-
resis of recombinant AMPKa2, the predominant a subunit in the
heart, also revealed a mobility shift that was dose-dependentlyCell Mexacerbated by H2O2 (Figure 4C), indicating that cysteine oxida-
tion in the a subunit is sufficient for aggregate formation. Consis-
tent with the biochemical data, immunofluorescent staining with
AMPKa antibody revealed a punctate pattern indicative of
AMPKa aggregation after H2O2 treatment (Figure 4D). Together,
these results suggest that Trx1 inhibits disulfide bond formation
in AMPKa during energy stress.etabolism 19, 232–245, February 4, 2014 ª2014 Elsevier Inc. 235
Figure 3. Trx1 Is an Essential Cofactor for AMPK Activation during Energy Stress
(A) Cardiomyocytes transduced with the indicated adenovirus were incubated with glucose-free medium for the indicated times. Cell lysates were analyzed by
immunoblot for p-AMPKa, AMPKa, p-ACC, ACC, Trx1, and a-tubulin. Statistical analyses of densitometric measurements of p-AMPKa and p-ACC are shown
(*p < 0.05 versus sh-con/0 hr; n = 3).
(B–D) Cardiomyocytes transduced with the indicated adenovirus were incubated with normal or glucose-free medium.
(B) Subcellular fractionation was performed to examine membrane Glut4 expression. Statistical analysis of densitometric measurement of membrane Glut4 is
shown (*p < 0.05 versus control; #p < 0.05 versus GD; n = 3).
(C) Lysates were analyzed by immunoblot for p-PFK-2 and PFK-2. Results are representative of three individual experiments. Glycolysis rate was examined (*p <
0.05 versus control; #p < 0.05 versus GD; n = 3).
(D) Cell viability was measured (*p < 0.05 versus control, #p < 0.05 versus GD; n = 3). Error bars represent SEM.
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down assays were performed with biotinylated iodoacetamide
(IAM). IAM covalently binds to cysteine thiol groups only when
they are in the reduced form. With increasing concentrations
of H2O2, the amount of IAM-labeled AMPKa decreased
significantly (Figure 4E). However, overexpression of Trx1
maintained the amount of reduced form AMPKa even in the
presence of H2O2 (10 mM) (Figure S4D). These data indicate
that AMPKa contains redox-sensitive cysteines that are rapidly
oxidized during oxidative stress and can be reduced by
Trx1. Although H2O2 did not significantly affect basal AMPKa
Thr172 phosphorylation, it dose-dependently suppressed
AICAR-induced phosphorylation and activation of AMPK
(Figures S4E–S4H). Thus, cysteine oxidation blocks AICAR-
induced AMPK activation, mimicking the effect of Trx1 down-
regulation during energy starvation. High-dosage (300 mM)
H2O2 inhibited AMPK activity in cardiomyocytes even at base-
line (Figure S4I) and caused strong oxidative aggregation of
AMPK (Figure S4J). In contrast, the same dose of H2O2
induced AMPK activation in HEK293 cells (Figure S4I), consis-
tent with previous findings (Zmijewski et al., 2010). There was236 Cell Metabolism 19, 232–245, February 4, 2014 ª2014 Elsevier Inno AMPK aggregation or decrease in monomeric AMPK in the
presence of H2O2 in HEK293 cells (Figure S4J), suggesting
that oxidative aggregation and the amount of monomeric/
reduced AMPK critically regulate AMPK activity in both cell
types.
To test whether AMPKa oxidation is reversible, cardiomyo-
cytes were sequentially treated with H2O2 and normal medium.
After removal of H2O2, reduced-form AMPKa reappeared and
reverted to normal levels (Figure 4F). To evaluate the relative
importance of Trx1 and GSH, which also mediates protein disul-
fide reduction, in reduction of oxidized AMPK, we preincubated
cardiomyocytes with either buthioninesulfoximine (BSO), an
inhibitor of GSH synthesis, or 2,4-dinitro-1-chlorobenzene
(DNCB), which prevents Trx recycling by inhibiting TrxR (Arne´r
et al., 1995). BSO decreased the GSH level by about 60%,
whereas DMSO and DNCB did not (Figure S4K). DNCB
completely prevented reduction and further enhanced oxidation
of AMPKa upon removal of H2O2, whereas DMSO (vehicle) and
BSO had no effect (Figure 4F). Thus, AMPKa oxidation is revers-
ible and Trx1, but not GSH, is required to reduce the oxidized
AMPKa in cardiomyocytes.c.
Figure 4. AMPK Is Oxidized and Forms Intermolecular Disulfide Bonds during Energy Stress
(A and B) AMPK oxidation was examined. Cardiomyocytes transduced with the indicated adenovirus were incubated with or without glucose (A) or H2O2 (B).
Lysates were analyzed by immunoblot with an AMPKa antibody under reducing or nonreducing conditions. Duplicate samples were run on 6% and 8% gels to
present the oxidized and reduced forms of AMPK, respectively. Molecular weights, as determined by a simultaneously run protein ladder, are shown. In most of
the following figures, the oxidized and reduced forms of AMPK are presented as described above. Results are representative of three individual experiments.
(C) Recombinant AMPKa2was incubated with H2O2 at the indicated concentrations for 10min, and AMPK oxidation was examined. Results are representative of
three individual experiments.
(D) Cardiomyocytes were treated with or without 100 mM H2O2 for 10 min and stained with AMPKa antibody (red) and DAPI (blue).
(E) Cardiomyocytes were treated with H2O2 at the indicated concentrations for 10 min. The extent of cysteine reduction in AMPKa was detected. Results are
representative of three individual experiments.
(F) Reduction of AMPKa depends upon the Trx1 system. Cardiomyocytes were preincubated with 100 mM BSO for 24 hr or 100 mM DNCB for 15 min and then
treated with H2O2 for 30 min to oxidize AMPK. The medium was replaced with H2O2-free medium containing DMSO alone or DMSO with either BSO (100 mM) or
DNCB (100 mM) for another 60 min. AMPK oxidation was examined as previously described. Results are representative of three individual experiments.
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Next, we investigated which AMPKa cysteine is sensitive to
oxidation. Amino acid sequence alignment showed that
Cys130 and Cys174 are the only two cysteines that are
completely conserved from yeast to mammals (Figure 5A). To
identify redox-sensitive cysteines, recombinant AMPKa2 was
treated with or without 10 mM H2O2 for 10 min. Reduced cyste-
ines were then irreversibly labeled with IAM, whereas oxidized
cysteines were first reduced with DTT and then labeled with
S-Methyl methanethiosulfonate (MMTS). Tandem mass spec-
trometry (MS/MS) showed that a peptide containing Cys174 of
AMPKa2 existed predominantly in an IAM-labeled (reduced)
form in the control group but that an MMTS-labeled (oxidized)
form appeared in the H2O2-treated group (Figure 5B), suggesting
that Cys174 is oxidized in response to H2O2. Cys130 andCys490
were also oxidized in response to H2O2 (Figures S5A and S5B).Cell MAt high doses of H2O2, Cys297, Cys382, and Cys543 were also
found to be oxidized (data not shown), suggesting that more
cysteines within the AMPKa2 subunit may be oxidized in the
presence of severe oxidative stress.
We examined whether Cys130 or Cys174 is involved in the
interactionwith the catalyticmotif of Trx1. As expected, the inter-
action betweenWTAMPKa2 and Trx1C35Swas enhanced in the
presence of H2O2 (Figure 5C). A single mutation to serine at
Cys130 (AMPKC130S) or Cys174 (AMPKC174S) did not abolish
the H2O2-induced increase in interaction between AMPKa2 and
Trx1C35S (Figure 5C, left panel). However, mutation of both
Cys130 and Cys174 to serine (AMPK2CS) did inhibit the H2O2-
induced increase in interaction with Trx1C35S (Figure 5C, right
panel). Addition of a third mutation to serine at Cys490
(AMPK3CS) did not further decrease interaction with Trx1C35S,
suggesting that Cys130 and Cys174 are the two major cysteinesetabolism 19, 232–245, February 4, 2014 ª2014 Elsevier Inc. 237
Figure 5. Conserved Cysteines Participate in the Intermolecular Disulfide Bond Formation in AMPK
(A) Amino acid alignment of the AMPK family kinase domain (amino acids 128–183 in Rat AMPKa2). The positions of conserved cysteine residues corresponding
to Cys130 and Cys174 in rat AMPKa2 are indicated by blue rectangles. The conserved phosphorylation site corresponding to Thr172 in AMPKa2 is indicated by a
red rectangle. The activation loop of AMPKa is indicated by a purple rectangle.
(B) The MS spectra of AMPKa2 peptide (172–188). The peptide in the control group contained MMTS-modified Cys174 (m/z 1754.79, corresponding to oxidized
thiol) as well as IAM-modified Cys174 (m/z 1765.81, corresponding to reduced thiol). In the H2O2-treated group, the intensity of the peak corresponding to
oxidized Cys174 was increased.
(C)Cos7cells transfectedwithFLAG-Trx1C35S-HAandMyc-taggedAMPKWTormutant plasmidswere treatedwithorwithout 100mMH2O2 for 30min. Interaction
between AMPK and the Trx1C35S-trapping mutant was evaluated with immunoblot analyses. Results are representative of three individual experiments.
(legend continued on next page)
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active site of Trx1.
AMPK2CS hadmarkedly reduced IAM labeling at baseline and
in response to H2O2, suggesting that Cys130 and Cys174 are
the major cysteines that undergo oxidation (Figure S5C, left
panel). Trx1 downregulation significantly reduced IAM labeling
of AMPK in Ad-AMPKWT-transduced cardiomyocytes at base-
line and further in response to GD (Figure S5C, right panel), sug-
gesting that endogenous Trx1 reduces Cys130/174. To investi-
gate whether AMPK molecules form intermolecular disulfide
bonds with each other, FLAG/HA- and myc-tagged AMPK
were coexpressed in Cos7 cells and coimmunoprecipitated.
FLAG-AMPKC130S-HA, in which only Cys174 is redox sensitive,
was used to evaluate disulfide formation at Cys174. H2O2
enhanced the interaction of FLAG-AMPKC130S-HA with myc-
AMPK WT, myc-AMPKC130S, and myc-AMPKC174S, but not
myc-AMPK2CS, and DTT abolished the effect (Figure S5D).
Thus, Cys174 in one molecule forms an intermolecular disulfide
bond with Cys130 or Cys174 in another molecule (Figure S5E).
The H2O2-induced mobility shift and decreases in monomeric
AMPK were partially attenuated in AMPKC130S- and
AMPKC174S-transduced myocytes compared to in AMPKWT-
transduced myocytes and were completely abolished in
AMPK2CS-transduced myocytes (Figure 5D), suggesting that
the electrophoretic mobility shift of AMPK is mediated by oxida-
tion of Cys130 and Cys174.
To determine whether Cys130 and Cys174 in AMPK are
oxidized in response to GD in situ, FLAG-AMPK-HA immunopre-
cipitated from cardiomyocytes was analyzed by quantitative
mass spectrometry (MS). MMTS labeling at Cys130 and
Cys174, reflecting the oxidized form, was slightly increased in
the GD-treated group and significantly enhanced in the same
group when endogenous Trx1 was knocked down (Figure 5E).
These data suggest that Cys130 and Cys174 are oxidized in
response to GD but that endogenous Trx1 effectively attenuates
this oxidation in cardiomyocytes.
Redox-Sensitive Cysteines Regulate AMPK Activity
It has been proposed that dimerization of the kinase domain of
yeast Snf1, a member of the Snf1/AMPK protein family, naturally
inactivates it by burying the activation segment and substrate-
binding site (Nayak et al., 2006). We speculated that oxidative
aggregation physically interferes with access of AMPKKs to
the activation domain of AMPK, thereby inhibiting its phos-
phorylation and activation. To test this hypothesis, AMPK phos-
phorylation assays were performed with a mixture of LKB1, an
AMPKK, and its regulatory subunits, STRAD and MO25, collec-
tively termed the LKB1 complex, before and after oxidation.
When phosphorylation preceded H2O2 treatment, AMPKa was(D) Cardiomyocytes transduced with the indicated adenoviruses harboring C-ter
effect of mutation of AMPK on its oxidation was examined.
(E) Cardiomyocytes transduced with N-terminal FLAG- and C-terminal HA-tag
medium for 2 hr in the presence or absence of Ad-sh-Trx1. Lysates were prepared
were reduced with TCEP followed by MMTS alkylation. Samples were then imm
analyzed by MS. The overlay extracted ion chromatograms of peptide
TSCMMTSGSPNYAAPEVISGR (B), corresponding to oxidized C174, in control (blu
Ratios of the oxidized peptide peak heights relative to those of the control groups
represent SEM.
Cell Mlabeled with radioactive ATP, and phosphorylated AMPKa was
observed at higher molecular weights after H2O2 treatment
(Figure 6A, lanes five and six). However, when H2O2 treatment
preceded the kinase reaction, radioactive labeling of AMPKa
was markedly attenuated (Figure 6A, lanes seven and eight),
suggesting that oxidized AMPK cannot be phosphorylated by
AMPKK.
To elucidate the functional significance of cysteine modifica-
tion in AMPK, the activities of AMPKC130S and AMPKC174S
were examined. AMPKWT phosphorylation and kinase activity
were enhanced by GD (Figure 6B). However, neither
AMPKC130S nor AMPKC174S was phosphorylated at Thr172
or activated in response to GD (Figure 6B). The AMPK protein
levels were similar for AMPKWT, AMPKC130S, and
AMPKC174S, and the b2 and g1 subunits bound to the mutants
to a similar degree as to AMPKWT (Figure 6B), indicating that the
mutations did not affect AMPK stability or heterotrimer complex
formation. Immunofluorescent staining showed that AMPKWT,
AMPKC130S, and AMPKC174S were all present in both cytosol
and nucleus (Figure S6A), indicating that the mutations did not
affect the subcellular distribution of AMPK.
To further clarify the role of Cys130 and Cys174 in mediating
AMPK activation, we generated ten different AMPKa2 mutants,
in each of which a cysteine residue was replaced with a serine.
Of these, only AMPKC130S and AMPKC174S failed to exhibit
kinase activity in response to energy starvation in intact cells
(Table S2). Although AMPKC106S exhibited a 20% reduction
in kinase activity compared to WT, Cys106 oxidation was never
observed, either in the MS experiments or as a change in the
mobility shift pattern. The other seven mutants showed normal
Thr172 phosphorylation and kinase activity. These data indicate
that Cys130 andCys174 are responsible for AMPK oxidation and
are critical in the regulation of AMPK activation.
In in vitro kinase assays, LKB1 phosphorylated GST-
AMPKWT and increased its kinase activity 6-fold. However,
AMPKC130S and AMPKC174S were not phosphorylated by
LKB1, and their kinase activities remained at baseline levels
even in the presence of LKB1 (Figures 6C and 6D). AMPK
mutants in which Cys130 or Cys174 was substituted with
alanine (AMPKC130A or AMPKC174A) were not phosphory-
lated or activated in vitro or in vivo (Figures S6B and S6C),
suggesting that structural modification of Cys130 or Cys174
inhibits AMPK activation. Similarly, AMPK, which had been
alkylated with either IAM or NEM to block free thiol groups,
was neither phosphorylated nor activated in the presence of
LKB1 (Figures S6D and S6E). Since oxidative aggregation
also prevents phosphorylation of AMPK by LKB1 (Figure 6A),
these results suggest that the structural integrity of Cys130
and Cys174 is required for AMPK phosphorylation andminal HA-tagged AMPK were incubated with or without H2O2 for 30 min. The
ged AMPK (FLAG-AMPK-HA) adenovirus were incubated with glucose-free
in the presence of 100mM IAM to label reduced cysteines. Oxidized cysteines
unoprecipitated with anti-FLAG agarose beads, and immunoprecipitates were
s LFQQILSAVDYCMMTSHR (A), corresponding to oxidized C130, and
e line), GD (green line), and GD plus Ad-sh-Trx1 (red line) samples are shown.
are also shown (*p < 0.05 versus control; #p < 0.05 versus GD; n = 5). Error bars
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Figure 6. Intact Cysteine Residues Are
Required for LKB1-Mediated Phosphoryla-
tion of AMPK
(A) Recombinant AMPKa2 was incubated with
LKB1 complex and H2O2, with arrows indicating
the order of treatment. AMPK phosphorylation and
oxidation were detected by autoradiography and
immunoblot with an AMPKa antibody, respec-
tively. Results are representative of three individ-
ual experiments.
(B) Cos7 cells transfected with either FLAG-AMPK
WT-HA or the indicated mutants were incubated
with glucose-free medium for 2 hr. After immuno-
precipitation with anti-FLAG agarose beads, levels
of AMPKa Thr172 phosphorylation and of bound
AMPK b2 and g1 subunits were evaluated. Alter-
natively, the immunocomplex was subjected to
AMPK kinase assay (*p < 0.05 versus WT/control;
#p < 0.05 versus WT/GD; n = 3).
(C and D) GST-AMPKa2 WT or mutants were
incubated with LKB1 complex.
(C) AMPK phosphorylation was detected by
autoradiography. Coomassie brilliant blue (CBB)
dye staining and anti-AMPKa immunoblot of the
recombinant substrates are also shown.
(D) Standard AMPK kinase assays were per-
formed using SAMS peptide as a substrate (*p <
0.05 versus WT/LKB1(); n = 3).
(E) Cos7 cells transfected with either FLAG-AMPK
WT-HA or the indicated mutants were incubated
with glucose-free medium for 30 min. Interaction
between LKB1 and AMPK was examined. Results
are representative of three individual experiments.
(F) Cos7 cells transfected with the indicated
plasmids were analyzed by immunoblot for
p-ACC, ACC, p-AMPKa, AMPKa, FLAG, and
GAPDH. AICAR treatment was used as a positive
control. Results are representative of three indi-
vidual experiments. Error bars represent SEM.
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the physical interaction of LKB1 with AMPKWT, but not with
AMPKC130S or AMPKC174S, was enhanced in response to
GD (Figure 6E), suggesting that the presence of cysteines at
130 and 174 is required for assembly of the LKB1/AMPK
enzyme-substrate complex and the subsequent phosphoryla-
tion/activation process during energy stress. Thus, alteration
of the structure of Cys130 or Cys174 through disulfide bond-
mediated oxidation, amino acid substitution, or chemical alkyl-
ation blocks AMPK activation.
To further confirm that the cysteine modifications specifically
affect LKB1 phosphorylation of AMPK, but not the intrinsic
kinase activity of AMPK, we generated constitutively active
AMPK (CA-AMPK), consisting of only the kinase domain of the
a2 subunit, with or without cysteine-to-serinemutations at amino
acids 130 and 174. Addition of the C130S, C174S, or 2CS muta-240 Cell Metabolism 19, 232–245, February 4, 2014 ª2014 Elsevier Inc.tion to CA-AMPK did not affect its kinase
activity, as evidenced by phosphorylation
of ACC (Figure 6F). Thus, it appears that
the conserved cysteines are required
for activation of WT AMPK through
AMPKK-mediated phosphorylation andconformational change, but not for kinase activity in CA-
AMPK, which does not require activation by AMPKK.
Functional Significance of Redox-Sensitive Cysteines in
AMPKa
We examined the functional effect of the CS mutants in vitro.
Endogenous AMPKa2 in cardiomyocytes was downregulated
by transduction with AMPKa2 shRNA adenovirus (Ad-sh-
AMPKa2) and then reconstituted with Ad-AMPK WT or CS
mutants to the same level of AMPK expression as in con-
trol myocytes (Figure S7A). AMPKa2 downregulation en-
hanced GD-induced cardiomyocyte death. Restoration with
the WT protein normalized GD-induced cell death to the
same level as in the control group (Ad-sh-con) but recon-
stitution with AMPKC130S or AMPKC174S did not (Fig-
ure S7B). In addition, overexpression of either AMPKC130S
Figure 7. HFD Induces AMPK Oxidation
in Vivo
(A) Tg-AMPKC174S and WT mice were subjected
to ischemia for 3 hr. Myocardial infarct area/area at
risk (% infarct size/AAR) is shown (*p < 0.05 versus
WT; n = 7).
(B and C) Tg-Trx1 and WT mice on C57BL/6J
background were fed chow or HFD for 20 weeks.
Heart lysates were analyzed by immunoblot for
p-AMPKa, AMPKa, Trx1, and GAPDH. The extent
of AMPKa cysteine reduction was analyzed.
Statistical analyses of densitometric measure-
ments of reduced AMPKa and p-AMPKa are
shown (*p < 0.05 versus WT/chow; #p < 0.05
versus WT/HFD; n = 3–4).
(D) Tg-Trx1 andWTmice were fed chow or HFD for
20 weeks and subjected to ischemia for 3 hr.
Myocardial infarct area/area at risk (% infarct
size/ARR) is shown (*p < 0.05 versus WT/chow;
#p < 0.05 versus WT/HFD; n = 5). Error bars
represent SEM.
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PFK-2 (Figure S7C).
We next evaluated the functional significance of the CS
mutations in vivo. Since AMPKC130S and AMPKC174S
behave the same with regard to both oxidation and kinase
activity, we focused on C174S. To this end, we generated
two lines of transgenic mice with high and low levels of
cardiac-specific expression of AMPKC174S (Tg-AMPKC174S)
(Figure S7D). Expression of AMPKC174S reduced the endoge-
nous AMPKa2 protein level, probably by destabilizing it
through competition for endogenous b and g subunit binding,
and was accompanied by decreased Thr172 phosphorylation
of AMPKa (Figure S7D). Tg-AMPKC174S (line 13) exhibited
greater myocardial infarction than WT mice in response to
ischemia (Figure 7A). Thus, intact Cys130 and Cys174 areCell Metabolism 19, 232–245required to promote cell survival during
energy stress both in vitro and in vivo.
HFD Enhances AMPK Oxidation
Obesity and metabolic syndrome are
associated with greater cardiovascular
mortality and increased susceptibility to
myocardial ischemia and heart failure
(Abdulla et al., 2008). We investigated
whether AMPK is oxidized during meta-
bolic stress using a mouse model of
obesity (Sciarretta et al., 2012). HFD
consumption by C57BL/6J mice for 18–
20 weeks induced AMPK inactivation in
the heart, accompanied by decreased
Trx1 expression, AMPK cysteine oxida-
tion, and exacerbation of myocardial
infarction following prolonged ischemia
(Figures 7B and 7D). However, increased
Trx1 expression in Tg-Trx1 prevented
AMPK oxidation and maintained AMPK
activity in the heart even after HFD
treatment (Figure 7C). Tg-Trx1 were alsoprotected against the HFD-induced exacerbation of myocardial
infarction (Figure 7D), suggesting that restoration of Trx1 rescues
HFD-induced myocardial injury by preventing AMPK oxidation.
DISCUSSION
We demonstrate in this study that AMPK is a critical target of
Trx1 oxidoreductase activity during energy starvation. In
response to energy stress, AMPK forms oxidative aggregates
through intermolecular disulfide bonds at the conserved
Cys130 and Cys174 residues, which inhibit phosphorylation of
AMPK by AMPKK. Trx1 supports AMPK activation by reducing
these key residues, acting as an essential cofactor during energy
starvation (Figure S7E). However, AMPK is oxidized and cannot
be activated in the presence of enhanced oxidative stress or, February 4, 2014 ª2014 Elsevier Inc. 241
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contribute to the pathogenesis of metabolic disorders and
enhance the risk of cardiovascular disease development, so
therapeutic strategies that prevent AMPK inactivation under
adverse conditions such as chronic oxidative stress and aging
may prove more effective.
Identification of Trx1 Targets during Myocardial
Ischemia Using Trx1-Trapping Mutant
Identifying Trx1 substrates has been difficult due to the highly
transient nature of the thiol-disulfide exchange reaction, but sub-
stitution of Trx1 Cys35 with serine halts the reaction midway,
trapping the substrate (Verdoucq et al., 1999). Although the
Trx1-trapping mutant offers a convenient way to study the Trx1
regulatory network in cells, it can also detect nonphysiological
interacting partners, usually containing surface disulfide bonds,
even if they are not redox regulated due to the very high reactivity
of the nucleophilic Cys32 (Hisabori et al., 2005). Thus, physiolog-
ical interaction between Trx1 and its potential substrates needs
to be carefully evaluated.
To our knowledge, this method has not been used to identify
relevant targets of Trx1 under stress in vivo. Using transgenic
mice expressing the Trx1-trapping mutant in the heart, we
were able to pull down peroxiredoxin, a well-known Trx1 sub-
strate, confirming the validity of this genetic mouse tool. We
used the mouse line with the lowest transgene expression to
avoid nonspecific binding.We confirmed the physical interaction
between Trx1 and AMPKa using multiple methods and showed
that Trx1-mediated reduction of AMPKa at Cys130 and
Cys174 is essential for AMPK function in the presence of energy
stress. Thus, we believe that AMPK is a physiological target of
Trx1. The Trx1-trappingmice, together with proteomics, detailed
protein-protein interaction studies, and functional analyses,
should allow us to identify additional functionally relevant Trx1
targets during other types of cardiac stress in vivo.
Trx1 Is a Cofactor of the AMPK Complex Necessary for
its Activation
A dynamic thiol exchange reaction occurs between the Trx1
active site and AMPK cysteines in the presence of oxidative
stress. However, Trx1 and AMPK interact with one another
even under unstimulated conditions in cardiomyocytes. We
speculate that this partially involves Trx1 domains other than
the catalytic motif, since Trx1C32S/C35S still interacted with
AMPK, allowing Trx1 to readily reduce AMPK when Cys130
and Cys174 are oxidized. Trx1 thus acts as an indispensable
cofactor of AMPK, suppressing oxidation and supporting activa-
tion of AMPK during energy stress.
The amino acid sequences around AMPKCys130 and Cys174
share some common features with those around cysteines in
NF-kB and Ref1 known to interact with Trx1 (Qin et al., 2000).
For example, the arginine at the P+2 position of Cys130 may be
important for strong hydrophobic interaction with Trx1, and the
glycine and leucine in the P4 positions of Cys130 and
Cys174, respectively, may allow interaction with the aromatic
ring of Trp31 in Trx1 (Qin et al., 2000). Both positions may help
stabilize the complex between Trx1 and its substrates. Further
investigation of the protein structure should clarify how Trx1
catalyzes reduction of AMPK at Cys130 and Cys174.242 Cell Metabolism 19, 232–245, February 4, 2014 ª2014 Elsevier InAMPK Is a Redox-Sensitive Kinase
Although AMPK is primarily thought of as an energy-sensitive
kinase, recent studies have indicated that its activity is also regu-
lated by oxidative stress. Several lines of evidence suggest that
ROS inhibit AMPK activity (Dolinsky et al., 2009; Saberi et al.,
2008), but no study has addressed whether the suppression is
mediated by direct posttranslational modification. Interestingly,
exogenous oxidant treatment stimulates AMPK by modulating
either LKB1 activity or intracellular AMP/ATP levels in some
transformed cell lines (Cao et al., 2008; Han et al., 2010). We
demonstrate here that ROS negatively regulate the activity of
AMPK in cardiomyocytes during energy starvation through direct
posttranslational modification. Why is AMPK regulated differ-
ently by ROS in different cell types? We speculate that both
the antioxidant level and the nature of the oxidative stress affect
the overall effect of ROS upon AMPK activity. For example, the
same dosage of H2O2 induces AMPK oxidation in cardiomyo-
cytes but not in HEK293 cells (Figure S4J). Compared to primary
cardiomyocytes, transformed cell lines may have elevated levels
of antioxidants such as Trx1 that prevent AMPK oxidation and
aggregation. AMPK activity may also be regulated by distinct
mechanisms under energy-sufficient and energy-deficient
conditions. In HEK293 cells, S-glutathiolation at Cys299 and
Cys304 of AMPKa1 is essential for H2O2-induced AMPK activa-
tion through modulation of the autoinhibitory domain under
energy-sufficient conditions (Zmijewski et al., 2010). Whether
Cys130 and Cys174 are modified under these conditions in
HEK293 cells is unknown, but mutation of Cys299 and Cys304
in AMPKa1 did not affect AICAR-induced AMPK activation,
consistent with our observation in cardiomyocytes that neither
Cys297 nor Cys302 in AMPKa2 is oxidized or involved in energy
starvation-induced AMPK activation. Thus, posttranslational
oxidative modifications of AMPK are stimulus dependent.
Mutation of the redox-sensitive cysteines to serines, which in
theory should mimic the reduced form, also inhibits AMPK acti-
vation, and modification of the cysteines with either chemical
alkylation or via mutation abolished the interaction between
AMPK and LKB1 and AMPK Thr172 phosphorylation. Thus,
intact and reduced thiols at Cys130 and Cys174 are prerequisite
for AMPK activation, and redox regulation at these cysteines is
essential for the AMPK-mediated survival effect during energy
stress. This mechanism also provides insight as to how H2O2
can stimulate AMPK in transformed cell lines such as HEK293,
in which a relatively high antioxidant capacity may keep
Cys130 and Cys174 in the reduced form even in the presence
of H2O2. Under such conditions, strong oxidative stress caused
by exogenous H2O2 may allow AMPK to be activated by oxida-
tion of another cysteine residue through some other posttransla-
tional modification, such as S-glutathiolation.
How Does Oxidation of AMPK Affect Its Structure and
Kinase Activity?
Crystal structure analyses show that the yeast Snf1 kinase
domain dimer is formed predominantly by hydrophobic interac-
tions between residues within the T loop activation segment and
the loop-aG region of the kinase domain (Nayak et al., 2006). The
interaction at the T loop activation segment takes place around
Thr210, corresponding to Thr172 in AMPK, and involves
the flanking residues, including Cys212, which corresponds toc.
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Waals interactions play a role in mediating the dimerization,
two mutations of the hydrophobic core of the dimer interface
(I257E and F261E) were not sufficient to disrupt Snf1 homodime-
rization in vivo, suggesting that other mechanisms may be
involved. Our results suggest that intermolecular disulfide bonds
involving Cys174 may be responsible for the dimer formation
in AMPK.
Snf1 dimerization buries the activation segment and
substrate-binding site deep inside the dimer, representing
a natural, inactive form of Snf1 (Nayak et al., 2006). Our results
show that oxidative modification and amino acid substitution
at Cys174 or Cys130 abolishes interaction between AMPK and
LKB1 and Thr172 phosphorylation by LKB1. Furthermore,
LKB1 cannot phosphorylate recombinant AMPK when the
kinase reaction follows oxidation of AMPK in vitro. We speculate
that the oxidative aggregate of AMPK physically interferes with
access of LKB1 to the AMPK activation domain. Given that
Cys130 is located on the surface of mammalian AMPK and close
to the activation domain, oxidation of Cys130 in mammalian
AMPK may also induce burial of the activation segment.
Since disulfide bond formation is a reversible process, it allows
for tight control of AMPK activity through the balance between
oxidative stress and the intact Trx1 system (Figure 4F). Indeed,
Trx1-dependent reduction of AMPK is essential for AMPK
activation by physiological stimuli such as energy starvation.
Disulfide bond formation during AMPK oxidation can also pre-
vent severe cysteine oxidation, which would irreversibly inhibit
its kinase activity. Thus, the intermolecular disulfide bond of
AMPK may also be adaptive against severe oxidative stress.
Biological Significance of AMPK as a Redox Sensor
How do myocardial ischemia and GD stimulate ROS produc-
tion in cardiomyocytes? We recently showed that GD activates
Nox4, a major isoform of the NADPH oxidase family that is
localized on intracellular membranes (Sciarretta et al., 2013).
Changes in the activity of the antioxidants and transporters
controlling intracellular and mitochondrial Ca2+ levels may
also contribute to increased ROS levels. In addition, activation
of AMPK stimulates energy production pathways, including
glycolysis and fatty acid oxidation, thereby indirectly increasing
mitochondrial workload and consequent electron leakage.
Interestingly, AMPK plays an essential role in upregulation of
Trx1 in cardiomyocytes, which in turn prevents AMPK oxida-
tion. AMPK activation also stimulates antioxidant capacity
during energy stress (data not shown), which could be an
adaptive mechanism to prevent ROS-induced damage. Thus,
AMPK and Trx1 stimulate one another’s activity, thereby help-
ing to maintain the homeostasis of both energy and redox
status in cardiomyocytes. We propose that AMPK has three
different statuses: oxidized (inactive), reduced (activatable),
and reduced and phosphorylated (active) (Figure S7E). The
relative proportions of each form are determined by the intra-
cellular energy status, ROS level, and Trx1 activity. Under
physiological conditions, AMPK mainly remains in its reduced
form in a Trx1-dependent manner. However, AMPK is oxidized
and cannot be activated in the presence of enhanced oxidative
stress or when Trx1 activity is suppressed. In our obese mouse
model, we also observed decreased Trx1 protein expression.Cell MThe dual effect upon Trx1 activity and Trx1 expression may
explain the enhanced AMPK oxidation and inactivation in these
animals. Oxidative stress has been shown to promote Trx1
degradation in vascular cells (Zschauer et al., 2011). Given
that AMPK positively regulates Trx1, inhibition of AMPK may
contribute to Trx1 suppression and ROS accumulation during
the development of obesity or diabetes, which would further
accelerate AMPK oxidation, leading to disruption of the redox
and energy balances. AMPK plays a protective role in several
human disorders, including myocardial ischemia, diabetes,
obesity, and cancers. Knowledge obtained from this investiga-
tion should be useful for the development of therapeutic stra-
tegies by which AMPK may be activated even under adverse
conditions such as oxidative stress and aging.
EXPERIMENTAL PROCEDURES
Transgenic Mice
Transgenic mice expressing either hTrx1C32S/C35S (Tg-Trx1C32S/C35S) or
WT hTrx1 (Tg-Trx1) were generated on an FVB background as described
previously (Yamamoto et al., 2003). Transgenic mice expressing either
hTrx1C35S (Tg-Trx1C35S) or AMPKC174S (Tg-AMPKC174S) were generated
on an FVB background using the a-myosin heavy chain promoter (courtesy of
J. Robbins, University of Cincinnati, Cincinnati) to achieve cardiac-specific
expression. Tg-Trx1 mice generated on a C57BL/6 background were used
in the HFD study. All protocols concerning animal use were approved by the
Institutional Animal Care and Use Committee at the New Jersey Medical
School, Rutgers Biomedical and Health Sciences.
Immunoblot Analysis
Heart homogenates or cell lysates were prepared using RIPA buffer containing
50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% deoxy-
cholic acid, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 0.5 mM 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride, 0.5 mg/ml aprotinin, and 0.5 mg/ml
leupeptin. Equal amounts of proteins (10–20 mg) were subjected to SDS-
PAGE. Nuclear and cytosolic fractions were prepared with NE-PER Nuclear
and Cytoplasmic Extraction Reagents (Pierce). After proteins were transferred
to a PVDF membrane, immunoblots were probed with the indicated anti-
bodies. Protein abundance was analyzed densitometrically and standardized
with a-tubulin or GAPDH.
For AMPK redox analysis, cardiomyocytes were incubated with ice-cold
PBS containing 20 mM NEM for 15 min to block free thiol groups immediately
after treatment and subsequently lysed with RIPA buffer containing 20 mM
NEM to prevent further cysteine oxidation during protein extraction. Equal
amounts of proteins were then subjected to SDS-PAGE with loading buffer
with or without BME.
Immunoprecipitation
Heart homogenates or cell lysates were prepared using lysis buffer containing
50mMTris (pH 7.4), 150mMNaCl, 1%Triton X-100, and 1mMEDTA. The lysis
buffer used to examine protein-protein interaction with Trx1 or its mutants was
supplemented with 20 mM NEM to avoid spontaneous thiol oxidation during
protein extraction or incubation. Lysates were incubated with 30 ml protein A
agarose-immobilized antibody or 30 ml FLAG-agarose beads (Sigma) for 2 hr
at 4C. Immunocomplexes were washed with lysis buffer three times and
eluted with 23 SDS sample buffer.
AMPK Kinase Assays
Immunocomplexes from Cos7 cells transfected with WT or mutant AMPK in
the presence of normal or glucose-free medium were subjected to a stan-
dard AMPK kinase assay using SAMS as a substrate. A total of 1 mg of
E. coli-expressed GST-AMPKa2 (WT or mutant) was maximally activated
using MgATP and AMPKK, and 5 ml of the mixture was subjected to a
standard AMPK kinase assay. The phosphorylation status of AMPK was
detected by autoradiography.etabolism 19, 232–245, February 4, 2014 ª2014 Elsevier Inc. 243
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Cardiomyocytes plated on 6 cm dishes were treated with H2O2 using the
indicated times and doses and lysed with RIPA buffer containing 200 mM
biotinylated-IAM (Sigma). The lysates were incubated with 25 ml streptavidin
agarose beads (Sigma) for 2 hr at 4C. After washing with lysis buffer three
times, biotinylated proteins were eluted with 23 SDS sample buffer and
subjected to immunoblot analysis.
Mass Spectrometry
Immunoprecipitated or E.coli-expressed proteins were separated by SDS-
PAGE. The gel band corresponding to AMPKa2 was trypsin digested in gel
without reduction/alkylation. The resulting peptides were subjected to liquid
chromatography-MS/MS analysis on a U3000 LC coupled with an Orbitrap
Velos tandem mass spectrometer (Thermo Fisher Scientific). MS/MS spectra
were searched against a Swissprot rat database. Methionine oxidation, Cys
methylthio (MMTS), and carbamidomethyl (IAM) modifications were set as
variable modifications. The selected ion chromatogram peak areas of
AMPKa2 peptides identified with either MMTS or IAM modifications were
used for relative quantification after normalization with the average peak areas
of two non-Cys-containing AMPKa2 peptides.
Statistical Analysis
All values are expressed as mean ±SEM. Statistical comparisons between
groups were conducted by unpaired Student’s t test or one-way ANOVA
followed by a Newman-Keuls comparison test. The value of p < 0.05 was
considered to be significant.
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